Eric Cox

💥 The Value of In-House Medical Affairs to the MSL 💥 Check out this weeks MSL Talk Podcast with Erlene Seymour, MD, Medical Director, US Medical Affairs Hematology at BeiGene who discusses the value of In House or HQ Medical Affairs to the MSL   Learn more about….   👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support 👉 What makes in house medical affairs so valuable to MSLs and to the organization 👉 Advice for MSLs in how they should view and interact with their inhouse counterparts 👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position 👉 What is it that helps MSLs stand out and separate themselves from the others   The MSL Talk Podcast will be available Tuesday May 14th, 2024 on all podcast platforms and the MSL Talk YouTube Channel.     MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers  

15

💥 The Value of In-House Medical Affairs to the MSL 💥 Check out this weeks MSL Talk Podcast with Erlene Seymour, MD, Medical Director, US Medical Affairs Hematology at BeiGene who discusses the value of In House or HQ Medical Affairs to the MSL Learn more about…. 👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support 👉 What makes in house medical affairs so valuable to MSLs and to the organization 👉 Advice for MSLs in how they should view and interact with their inhouse counterparts 👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position 👉 What is it that helps MSLs stand out and separate themselves from the others The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers

15

2 Comments

💥 The Value of In-House Medical Affairs to the MSL 💥 Check out this weeks MSL Talk Podcast with Erlene Seymour, MD, Medical Director, US Medical Affairs Hematology at BeiGene who discusses the value of In House or HQ Medical Affairs to the MSL Learn more about…. 👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support 👉 What makes in house medical affairs so valuable to MSLs and to the organization 👉 Advice for MSLs in how they should view and interact with their inhouse counterparts 👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position 👉 What is it that helps MSLs stand out and separate themselves from the others The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers

14

5 Comments

💥 SUPER MSL: The Quest to Become the TOP MSL on Your Team💥 Don't miss this weeks MSL Talk podcast with Daniel Snyder, Ph.D., Senior Medical Affairs & HEOR Leader who discusses the differentiators for MSLs that will make you stand out and become the top MSL on your team. Learn more about….   👉 The qualities and differentiators of a “Super MSL” 👉 The skills and attributes that make MSLs stand out relative to their peers 👉 What common mistakes do MSLs need to avoid to 👉 What MSL Team leader should do to encourage and entice ideal MSL skills The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel.     MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #MSLtalk #careers  

32

3 Comments

💥 SUPER MSL: The Quest to Become the TOP MSL on Your Team💥 Don't miss this weeks MSL Talk podcast with Daniel Snyder, Ph.D., Senior Medical Affairs & HEOR Leader who discusses the differentiators for MSLs that will make you stand out and become the top MSL on your team. Learn more about…. 👉 The qualities and differentiators of a “Super MSL” 👉 The skills and attributes that make MSLs stand out relative to their peers 👉 What common mistakes do MSLs need to avoid to 👉 What MSL Team leader should do to encourage and entice ideal MSL skills The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLtalk #careers

27

1 Comment

𝐑𝐄𝐆𝐔𝐋𝐀𝐓𝐎𝐑𝐘 𝐑𝐎𝐔𝐍𝐃𝐔𝐏 ⚛️ The FDA has released new draft guidance recommending best practices for multi-regional clinical trials (MRCTs) in oncology. Sponsors are encouraged to ensure that the outcomes of global oncology clinical development programs are understandable for US patients in support of marketing applications. 🌐 The FDA's final guidance on decentralized clinical trials (DCTs) clarifies several concerns raised by clinical experts and industry stakeholders regarding the earlier draft. This includes detailed requirements for maintaining a task log for healthcare providers, guidelines for physical inspections, and addressing challenges related to data variability in DCTs. 🤖 As the use of artificial intelligence (AI) tools, particularly generative AI, expands, experts remind regulatory professionals to prioritize the human aspect. Although these tools offer significant benefits, they necessitate human oversight and interpretation to be fully effective. During the opening plenary session, experts discussed how AI can be utilized across various sectors, the potential of this technology, and the hurdles in achieving its full benefits. Panelists included Ryan Kurtzman from the City of Long Beach, Bradley Thompson of Epstein Becker Green, Michelle Jump from MedSec, and Jay Mashburn from Recursion Pharmaceuticals, with moderation by Megha Iyer of Thermo Fisher Scientific. 🧬 As biosimilars gain market presence, they are generating competition with original products. However, patient adoption of biosimilars varies based on demographics, location, care setting, prescriber specialties, and types of insurance, according to two recent studies in Health Affairs. 🌐 The FDA has observed a rise in complete response letters (CRLs) issued to sponsors of biologics license applications (BLAs) over the last decade, with facility deficiencies being the most common reason cited, according to Leslie Rivera Rosado, a supervisory interdisciplinary scientist at the agency's Center for Drug Evaluation and Research (CDER). #Pharmaceuticals #Biotechnology #LifeSciences #PharmaNews #Biotech #HealthcareInnovation #DrugDevelopment #ClinicalResearch #Biopharma #PharmaTech #MedicalResearch #Healthcare #BioPharmaceuticals #PharmaIndustry #BiotechIndustry #PharmaCareers #MedicalInnovation #NewDrugs #Genomics #BiotechNews

14

AbbVie Completes Acquisition of Cerevel Therapeutics 🔶 Cerevel's clinical-stage assets complement AbbVie's emerging #neuroscience pipeline and leading on-market brands in psychiatry, migraine and #parkinsonsdisease 🔶 Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for #schizophrenia 🔶 Cerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decade 🔶 AbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $2.92-$2.96 Full article in the comments ⬇

36

1 Comment

How should a biopharmaceutical company measure its progress? Ask any of us at Alnylam Pharmaceuticals, and our answer is rooted in our commitment to delivering the full potential of #RNAiTherapeutics for patients who are waiting. Driving this bold commitment is, and always has been, our Patient Access Philosophy, which holds us accountable to measure the success of our innovation based on the significance of patient access, outcomes, and societal impact. We have made much progress and know there is more to do. That is why we are very pleased to announce the evolution of our Patient Access Philosophy, with principles that embrace the responsibility we have as an independent biopharmaceutical company with a unique opportunity to positively impact the patient journey with innovative medicines like #RNAi therapeutics. I’ve shared my perspective on the importance of the Philosophy in Alnylam’s Newsroom https://bit.ly/3WdnzsO. #PatientAccess #RNAinterference #biotech #biopharma

91

2 Comments

Led by Markus Renschler, MD, Light Horse Therapeutics has made significant progress in the oncology space with a $62M #SeriesA funding round led by MPM BioImpact and Omega Funds, alongside Novartis Venture Fund. This marks a big step for their work in developing LHT-001, a promising candidate targeting critical cancer pathways. In parallel, their partnership with Novartis could be worth up to $1B, combining Light Horse's innovative pipeline with Novartis' expertise in oncology drug development and commercialization. This collaboration has the potential to address unmet needs in cancer treatment and accelerate progress in this critical field. #Biotech #Oncology #Immunology #Innovation #LightHorseTherapeutics #Novartis #MPMBioImpact #OmegaFunds

7

🚀 Exciting News 🌍 Teva Pharmaceuticals, an Israeli company and the largest generic drug manufacturer in the world, just signed a major agreement with mAbxience. Together, they will develop and market a biosimilar version of a cutting-edge cancer therapy. 💡 What's the deal? Teva and mAbxience will focus on creating a biosimilar to a PD-1 inhibitor, a key oncology drug that blocks certain proteins in immune cells, helping the body’s immune system attack cancer cells more effectively. 🎯 Why is this important? - Affordable access: This biosimilar version will make an expensive cancer treatment much more accessible at a lower cost. - Wider reach: More patients around the world will now be able to benefit from this life-saving treatment! 🇮🇱 Proud to see Teva lead the way in making advanced treatments affordable and accessible globally! #PharmaInnovation #TevaPharma #Biosimilars #AffordableHealthcare #CancerTreatment #IsraelInnovation #ILMEDS

2

1 Comment

We started out Q1 with cautious optimism and the numbers continue to show the confidence was warranted. Biopharma M&A activity more than doubled nationally during the year’s first three months, coinciding with a rebound in venture capital deals as well as a flurry of IPOs. These are all good signs that the drug development cycle is normalizing and should translate into additional funding being available at the seed and Series A stages. Certain to be on the minds of funders and startups attending #AlignSummit24 on Thursday! https://lnkd.in/erEiJm6S  

112

5 Comments

What an interesting read on the shift from traditional patient recruitment methods in rare disease! Learn more about how to optimize patient-driven site engagement in my team member’s blog: https://bit.ly/4eHoBn4

3

Please read my interview with Ken Keller, Chairman of the Board, President, and CEO of Daiichi Sankyo, Inc., on Innovating Oncology Treatment: The Role of ADCs and Strategic Partnerships in Shaping the Future of Cancer Care.

12

2 Comments

🔥 Clinical trial industry, get ready for this gamechanger! Greenphire and Suvoda are merging to create the most comprehensive patient support provider. Read the announcement below: https://lnkd.in/eEnCRdBe

29

2 Comments

As #BreastCancerAwareness Month comes to a close, let’s take a look at how far treatment has come—and the promising path ahead. Thanks to continued R&D, we’re seeing breakthroughs in early detection and targeted treatments that have made a real difference in patient outcomes, giving us powerful new tools to improve outcomes. Today, molecular profiling enables treatments tailored to each patient, while non-invasive liquid biopsies provide precise disease monitoring without the need for invasive procedures. It’s all helping to make a genuine difference. Leading researchers and executives are dedicated to making these developments possible. Daniel O'Day and Gilead Sciences, through Immunomedics, have introduced Trodelvy—an antibody-drug conjugate that’s offering new hope for those with metastatic triple-negative breast cancer. Meanwhile, Vas Narasimhan and the team at Novartis are leading research into novel biomarkers, promising earlier diagnosis and more customized therapies. And Eric Lefkofsky at Tempus AI has set a new standard with AI-driven data analysis, which is rapidly expanding our ability to personalize treatments at scale. It’s exciting to think about the future of precision medicine and how these advancements could reshape cancer care, getting us closer to a time when every patient receives the most effective treatment possible. #BreastCancerAwareness #CancerResearch #PrecisionMedicine #Innovation #Biotech

3

As we wrap up 2024, I want to thank you all for your continued engagement and thoughtful discussions around the evolution of our industry. I wish you, your teams, and loved ones a wonderful holiday season and a prosperous new year ahead! Hot Take for 2025: The End of Traditional Pharma BD 2025 will mark the beginning of the end for traditional pharma business development - but not for the reasons most think. While platform licensing deals have historically disappointed, AI is finally changing this paradigm. Why is this time different? Previous platform deals failed due to: -Technical limitations (delivery challenges, limited scale) -Complex deal structures killing momentum -Misaligned incentives between parties -High costs without clear ROI paths But AI platforms are fundamentally changing the game through: -Dramatically lower costs per candidate -Rapid validation cycles -Cross-therapeutic area adaptability -Continuous learning improving value The evidence is mounting: -Insitro's successful Gilead/BMS partnerships -Recursion's pharma collaborations showing results -Insilico Medicine's clinical progress -Major AI investments by AZ, Novartis, GSK Looking ahead: Smart pharma companies will shift from "multiple shots on goal" to securing "better targeting systems" through AI platforms. We'll see more mega-deals focused on platform access rather than single assets. The industry's skepticism of platform deals is warranted given history. But AI's unique characteristics - speed, scalability, and proven ability to generate clinical candidates - make this time genuinely different. Thoughts? Would love to hear your perspectives on how AI is reshaping BD strategy in your organization. #Pharma #Biotech #AI #BusinessDevelopment #FutureOfPharma #Innovation

26

Very tough week for the Parkinson's community with back-to-back failures of Roche's prasinezumab and UCB's minzasolmin, both targeting alpha-synuclein proteins: https://lnkd.in/dHfwzyjg A lot of data remains to be unpacked, but prasinezumab now qualifies as one of the most heavily studied Parkinson's drugs ever. Over the past 11 years, it has been tested in >900 patients, including some who have been on it for >4 years in an open-label extension. In 2025, we’ll join the rest of the Parkinson's community in reflecting on what these results teach us about alpha-synuclein’s role in Parkinson’s disease—and, more broadly, how to improve the process of drug development for Parkinson’s going forward. One big missing piece is the lived experience of patients who participated, especially those in the 4+ year open-label extension. I hope their stories emerge in the coming months. 🧠

162

16 Comments

Private equity firms bid on Sanofi's $16B+ consumer health business: Bloomberg - Fierce Pharma As private equity firms reportedly place their bids, Sanofi may soon follow in the footsteps of GSK and Johnson & Johnson with the separation of its consumer health unit. Sanofi has received separate offers from private equity firms PAI Partners and Clayton, Dubilier & Rice for its consumer health business, which could be valued at 15 billion euros ($16.7 billion) or more, Bloomberg reported Tuesday, citing people close to the matter. Sanofi will likely make a decision on the fate of its consumer health unit in the coming days, Bloomberg’s sources said. Sanofi could pursue a spinoff if the proposed deals fall short, the anonymous sources added. PAI and Clayton, Dubilier & Rice were both singled out as potential buyers in a separate Bloomberg report from June. When reached for comment, Sanofi pointed Fierce Pharma to an announcement from Oct. 2023 stating that the company was reviewing potential separation scenarios for its consumer health business, with a transaction expected in 2024’s fourth quarter “at the earliest.” Sanofi has yet to decide on the fate of its consumer health business and expects to “select the best option for Sanofi and its stakeholders in the next few months,” the spokesperson added. “We are keeping all options open, including a listing, and a sale, to maximize value creation for all our stakeholders,” the spokesperson said, promising to provide more information as the situation evolves. https://lnkd.in/eXGmQFVg

12